Index

A
Adolescent insomnia
behavioral sleep restriction
self-imposing sleep restriction, 99
treatment of, 99
bipolar disorder, 91
circadian core body temperature
rhythm, 91
clinical interview and questionnaires, 89
delayed sleep phase disorder
circadian timing system, 95
treatment of, 96
dim light melatonin onset (DLMO), 92
gender differences, 85–88
hormonal changes, 91
inadequate sleep hygiene
differentiating, 97
increased caffeine intake, 96
prevalence rates of, 97
treatment of, 97
insomnia vs. DSPD, 92
MEQ, 89–90
night-and day-time features, 89
PDS, 89
prevalence rates of, 92
puberty, 85
Spielman behavioral model of, 90
treatment of
cognitive behavioral therapy, 93
differential diagnoses of, 92–93
self-relaxation training, 93
sleep hygiene education, 94
sleep restriction therapy (SRT), 94
stimulus control therapy, 93

B

C
Catechol-O-methyl transferase (COMT), 263
Cesarean birth, 225, 233, 236
Childbearing age, 64–65
Circadian rhythm control
men vs. women, 76–77
process C, 76
process S, 76
SCN, 76
Climacteric syndrome, 267
Cognitive behavioral therapy (CBT)
biofeedback, 122
hypnotic agents, 122
menopausal insomnia, 305
paradoxical intention, 122
pharmacological principles, 122
primary insomnias, 123
relaxation training, 121
stimulus control therapy, 121
Confusional arousals
benzodiazepines, 194
clinical findings, 191–192
polysomnographic findings, 192–193
treatment
hypnosis and environmental change, 195
mood altering medications, 194–195
sexsomnia, 195
Continuous positive airway pressure (CPAP)
insomnia, 232
life cycle impact, 44
OSA
advantage of, 254
fetal outcomes, 251
nasal CPAP, 165
sleep-disordered breathing, 307
Delayed sleep phase syndrome (DSPS)
actigraphy, 78, 79
chronotherapy, 80
clinical evaluation, 78
clinical research, 77
pharmacotherapy, 80–81
phototherapy, 80
sequelae of, 77–78
Disorder of initiating and maintaining sleep (DIMS), 10
Disorder of initiating sleep (DIS), 10
Disorder of maintaining sleep (DMS), 10
Dream-enacting behaviors (DEB), 196, 198–200

Epidemiology
bruxism, 17
circadian rhythm sleep disorders, 17
hypersomnias, 12–13 (see also Excessive daytime sleepiness)
insomnia
benzodiazepines usage, 12
Caucasian menopausal women, 12
DIMS, 10
DIS, 10
DMS, 10
job-related stress, 11
luteal phase, 11
peri vs. postmenopausal women, 12
during pregnancy, 11–12
in prepubertal children, 11
shift-working nurses, 11
short sleep duration, 11
obstructive sleep apnea syndrome (OSAS)
age, 14
apnea–hypopnea, 13
habitual alcohol intake, 15
pre and postmenopausal women, 14
pregnancy, 15
risk factors, 14
sex hormones role, 14
weight, 14
REM, 16–17
restless legs syndrome (RLS)
in nulliparous women, 16
PLMD, 16
during pregnancy, 16
sleep duration and mortality, 9
sleep paralysis and hypnic hallucinations, 17
Epworth sleepiness scale (ESS), 172
Excessive daytime sleepiness, 12–13
Excessive daytime sleepiness (EDS)
behaviorally induced insufficient sleep syndrome, 181
diagnostic tests
MSLT, 173
MWT, 173
PSG, 173
ESS, 172
hypersomnia
drug/substance, 182, 183
medical condition, 182
idiopathic hypersomnia
diagnostic criteria, 180, 181
pathophysiology, 181
prevalence of, 180
treatment, 181
narcolepsy
cause of, 175
genetics/pathophysiology, 176
ICSD-2, 174, 175
treatment, 176–177
with and without cataplexy, 175
primary sleep disorders, 173
recurrent hypersomnia
diagnosis, 179
diagnostic criteria, 177, 178
OCP, 178
pathophysiology, 179
treatment, 179–180

Female-predominant parasomnias
sleep-related dissociative disorders
clinical findings, 205–206
polysomnographic findings, 207
treatment, 207
sleep-related eating disorder
clinical findings, 201–204
treatment, 204–205
Functional residual capacity (FRC), 244, 253

Gamma-hydroxy-butyrate (GHB), 177
Gender bias, 3
Gestational diabetes mellitus (GDM), 251, 252
Gestational restless legs syndrome (gRLS)
clinical presentation, 220
epidemiologic considerations, 218
etiology of, 219–220
treatment options for, 220–221
Hormone replacement therapy (HRT)
  objective awakening quality
    intellectual and mnestic performance, 280, 282
    psychomotor performance, 281–283
    psychophysiological measures, 282
    periodic leg movements, 278–279
    respiratory events and snoring, 276–279
    sleep architecture, 275, 277
    sleep-disordered breathing, 327–328, 332–333
    sleep initiation and maintenance, 275, 276
  subjective sleep and awakening quality, 279–281

Hypersomnia
  drug/substance, 182, 183
  medical condition, 182
  recurrent hypersomnia (see Recurrent hypersomnia)

Hypersomnolence, 171, 172

Idiopathic hypersomnia (IH)
  diagnostic criteria, 180, 181
  pathophysiology, 181
  prevalence of, 180
  treatment, 181

Insomnia
  adolescent (see Adolescent insomnia)
    age, 28
    air travel, 28
    case history, 29
  CBT
    biofeedback, 122
    hypnotic agents, 122
    paradoxical intention, 122
    pharmacological principles, 122
    primary insomnias, 123
    relaxation training, 121
    sleep restriction consolidation, 121
    stimulus control therapy, 121
  comorbid insomnias, 124
  depression, 284
  doxepin, 122
  evaluation of
    objective awakening quality, 271–272
    objective sleep quality, 271
  GABAA receptor agonist, 122
  gabapentin, 122

HRT
  and objective awakening quality, 280–283
  periodic leg movements, 278, 279
  respiratory events and snoring, 276–279
  sleep architecture, 275, 277
  sleep initiation and maintenance, 275, 276
  subjective sleep and awakening quality, 279–281

menopausal (see Menopausal insomnia)

postpartum
  clinical assessment, 233, 234
  co-sleeping and bed-sharing, 234–235
  depression, 235–236
  infant temperament and maternal, 236–237
  lactation and breastfeeding, 233, 234
  sleep changes, 238

pregnancy
  clinical assessment, 227
  CPAP, 232
  labor and delivery, 232–233
  leg sensations, 228–230
  medication risk, 229–230
  nighttime awakenings, 226, 227
  preeclampsia, 231
  RLS, 228
  sleep changes, 238
  snoring and obesity risk factors, 230–232

pregnancy-related insomnia, 123–124

response to medications
  alcohol, 128
  anticonvulsants, 128–129
  antihistamines, 128
  benzodiazepines, 125
  eszopiclone, 126–127
  herbal supplements, 129–130
  hypnotics, 128
  melatonin agonists, 129
  orexin receptor antagonists, 130
  sedating antidepressants, 127
  sedating antipsychotics, 128
  zaleplon, 126
  zolpidem, 125–126

sleep hygiene, 28, 29

statistics and sample size
determination, 272

study design and patients, 270–271

subjective sleep and awakening quality
evaluation of, 271
Insomnia (cont.)
insomniac postmenopausal syndrome
patients vs. normal controls,
272–274
vasomotor symptoms and depression, 28
Insomniac postmenopausal syndrome patients
Climodien A, 280
morning/evening thymopsychic
findings, 281
morning intellectual and mnestic
performance, 282
and normal controls
objective sleep variables, 273
sleep profile, 273
thymopsychic, and noopsychic
variables, 274
psychomotor performance, 283
respiratory variables, 278
sleep architecture, 277
sleep initiation and maintenance, 276
snoring and periodic leg movements, 279
*International Classification of Sleep
Disorders*, 2nd Edition (ICSD-2),
95, 173–175, 180

K
Kleine-Levin Syndrome (KLS)
diagnostic criteria, 178
pathophysiology, 179
treatment, 179–180
Kupperman index, 270

L
Lactation
and breastfeeding, 233, 234
chlordiazepoxide and lorazepam, 48
guidelines for, 48
hypnotic medication, 124
medication risk, 229–230
prolactin levels, 221
Late luteal phase (LLP), 26
Life cycle impact
menstrual cycle (see Menstrual cycle)
perimenopause
hot flashes, 49–50
HRT, 52
mood disorders, 51
movement disorders, 52
pain disorders, 52
sleep-disordered breathing, 50–51
thorugh sleep history, 52
postpartum period

data collection procedures, 45
feeding method, 46
infant’s sleep and feeding schedule, 45
psychotropic medication, 48
recommendations for, 46–47
sleep aids, 48
sleep deprivation, 47–48
pregnancy
benzodiazepines usage, 42
diazepam, 42–43
during first trimester, 40
preeclampsia, 43
RLS, 44–45
second and third trimesters, 41
sleep aids, 42
snoring, 43
total sleep time (TST), 41
treatment of, 42

M
Maintenance of wakefulness test
(MWT), 173
Maternal insomnia, 236–237
Melatonin, 263
Menarche and adolescence
insomnia, 59–60
restless legs syndrome, 60
sleep-disordered breathing, 60
sleepiness, 61
Menopausal insomnia
aging, 313
antidepressants, 303
antidopaminergic drug, 303
bellergal, 304
causes of, 293, 294
CBT, 305
climacterium
and sleep, 298–300
symptoms of, 297
vaginal dryness, 297
clonidine, 304
etiology of, 302–303
female sex steroids and sleep
estrogen, 300–302
progestogens, 302
management of, 295, 296
medical disorders
age, 309
alpha sleep activity, 311
circadian pacemaker, 311
COPD, 309
duloxetine, 311
fibromyalgia (FM), 310
Menopause

definition, 262
fatigue, 267
insomnia (see Insomnia)

OSA
HRT, 327–328, 332–333
mechanisms, 331
obesity and fat redistribution, 335
risk factor, 325–327
SDB (see Sleep-disordered breathing)
upper airway anatomy and mechanics, 335–337
ventilatory responsiveness, 333–335
restless legs syndrome, 66–67
RLS
estrogen, 262–263
melatonin, 263
postmenopausal women, 264
sleep-disordered breathing, 67–68

Menstrual cycle
dysmenorrhea, 40
late luteal phase, 38–39
methodological factors, 38
OSAHS, 140
PMS/PMDD, 39–40
premenstrual hypersomnia, 40
premenstrual insomnia, 38

Menstrual-related hypersomnia
diagnosis, 179
diagnostic criteria, 178

Obstructive sleep apnea (OSA)
apnea-hypopnea index, 153
BMI vs. RDI, 162, 163
CPAP, 30
differential diagnosis for, 154
epidemiology, 155, 156
insulin sensitivity, 163
lifestyle changes, 165
mechanisms, 331
nasal CPAP, 165
obesity and fat redistribution, 335
overnight polysomnography (oPSG), 153
vs. parasomnias, 200

O
Objective awakening quality
evaluation of, 271–272
HRT
intellectual and mnestic performance, 280, 282
psychomotor performance, 281–283
psychophysiological measures, 282

N
Narcolepsy
cause of, 175
diagnostic criteria, 175
genetics/pathophysiology, 176
ICSD-2, 174, 175
treatment, 176–177

Nocturnal dissociative disorders, 206
Non-rapid eye movement (NREM)
clinical findings, 191–192
polysomnographic findings, 192–193
treatment, 193–195

pathophysiology, 179
treatment, 179–180
Modafinil, 176–177
Morningness eveningness questionnaire (MEQ), 89–90

Multiple sleep latency test (MSLT), 173, 179

N
Narcolepsy
cause of, 175
diagnostic criteria, 175
genetics/pathophysiology, 176
ICSD-2, 174, 175
treatment, 176–177
Nocturnal dissociative disorders, 206
Non-rapid eye movement (NREM)
clinical findings, 191–192
polysomnographic findings, 192–193
treatment, 193–195
Obstructive sleep apnea (OSA)
apnea-hypopnea index, 153
BMI vs. RDI, 162, 163
CPAP, 30
differential diagnosis for, 154
epidemiology, 155, 156
glucose and insulin levels, 163, 164
lifestyle changes, 165
mechanisms, 331
nasal CPAP, 165
obesity and fat redistribution, 335
overnight polysomnography (oPSG), 153
vs. parasomnias, 200
pathophysiology
obesity, 160
pharyngeal muscles, 159
plasma TNFα (alpha), 160, 161
visceral body fat, 160, 161
physical examination, 153
polysomnogram (PSG), 30
pregnancy
fetal outcome, 252–253
gestational diabetes, 251–252
Obstructive sleep apnea (OSA) (cont.)
  hypertensive disorders, 246, 249–251
  influence of, 253
  management of, 253–254
  medical literature, 245–248
  preeclampsia, 249–251
  pregnancy-induced hypertension, 249–250
  prevalence of, 326
  sequelae, 157–158
  sleep-disordered breathing
    characteristics, 329–330
    clinical presentation, 330
    estrogen on, 331
    hormone replacement therapy, 327–328, 332–333
    sleep apnea severity, 328–329
  symptoms of, 153, 154
  UARS, 29–30
  upper airway anatomy and mechanics, 335–337
  UPPP, 165
  ventilatory responsiveness, 333–335
  visceral body fat, 165

Obstructive sleep apnea–hypopnea syndrome (OSAHS)
  adverse consequences, 140
  gender differences in, 138
  hormones role
    estrogen, 137
    progesterone, 136–137
  hypothyroidism, 142
  management of
    alcohol avoidance, 144
    behavioral treatment, 144
    continuous positive airway pressure, 145
    nasal symptoms, treatment, 144–145
    oral appliances, 145–146
    positional therapy, 144
    sedatives avoidance, 144
    uvulopalatopharyngoplasty (UPPP), 146
    weight loss, 144
  menstrual cycle, 140
  polycystic ovary syndrome, 142
  polysomnographic features, gender differences, 143
  pregnancy and preeclampsia, 141–142
  premenopausal vs. postmenopausal, 143
  prevalence, 135–136
  signs of, 139–140
  symptoms, 138–139

Oral contraceptive pill (OCP), 178, 180

P
Parasomnias
  clinical evaluation, 189–190
  DEB, 198–200
  definition, 187
  female-predominant parasomnias
    sleep-related dissociative disorders, 205–207
    SRED, 201–205
  gender predominance, 189
  NREM sleep
    clinical findings, 191–192
    polysomnographic findings, 192–193
    treatment, 193–195
  vs. OSA, 200
  during pregnancy, 207
  recurrent isolated sleep paralysis
    clinical findings, 199
    polysomnographic findings, 200
    treatment, 200
  REM sleep
    clinical findings, 196–197
    diagnosis, 197
    treatment, 198

Perimenstrual hypersomnia, 4
Periodic limb movement disorders (PLMD), 16, 93, 108, 109, 205, 217, 284
Periodic limb movements of sleep, 31
Pittsburgh Sleep Quality Index (PSQI), 279, 286
Polycystic ovarian syndrome (PCOS)
  BMI vs. RDI, 162, 163
  chronic anovulation, 152
  epidemiology, 154–155
  glucose and insulin levels, 163, 164
  hirsutism, 152
  hyperandrogenemia, 152–153
  insulin sensitivity, 163
  NIH vs. Rotterdam criteria, 151, 152
  pathophysiology, 158–159
  sequelae of, 156, 157
Polysomnogram (PSG), 173, 179
Postpartum insomnia
  clinical assessment, 233, 234
  co-sleeping and bed-sharing, 234–235
  depression, 235–236
  infant temperament and maternal, 236–237
  lactation and breastfeeding, 233, 234
  sleep changes, 238
Pramipexole, 205
Preeclampsia, 231, 249–250
Pregnancy
insomnia, 61–62
clinical assessment, 227
CPAP, 232
labor and delivery, 232–233
leg sensations, 228–230
medication risk, 229–230
nighttime awakenings, 226, 227
preeclampsia, 231
RLS, 228
sleep changes, 238
snoring and obesity risk factors, 230–232
iron deficiency, 62
nicotine usage, 26–27
OSA, 27
fetal outcome, 252–253
gestational diabetes, 251–252
hypertensive disorders, 246, 249–251
influence of, 253
management of, 253–254
medical literature, 245–248
preeclampsia, 249–251
pregnancy-induced hypertension, 249–250
parasomnias, 207
positive airway pressure, 64
respiratory system, changes in, 244–245
restless legs syndrome, 62–63
etiology, 219–220
prevalence during, 218
RLS, 27
sleep architecture and quality, 243–244
sleep-disordered breathing, 63–64
snoring, 27, 245
Premenstrual dysphoric disorder (PMDD), 26, 39, 40
Premenstrual syndrome (PMS), 26

R
Rapid eye movement (REM)
clinical findings, 196–197
diagnosis, 197
treatment, 198
Recurrent hypersomnia
diagnosis, 179
diagnostic criteria, 177, 178
OCP, 178
pathophysiology, 179
treatment, 179–180
REM sleep behavior disorder (RBD), 195–196
clinical findings, 196–197
diagnosis, 197
treatment, 198
Restless legs syndrome (RLS), 30–31
diagnosis of, 108, 112–113
dopaminergic dysfunction, 111
epidemiologic considerations, 218
epidemiology, 109–110
etiology, 110
gRLS (see Gestational restless legs syndrome)
IRLSSG standard criteria, 107–108
iron deficiency, 111
management
alcohol, 114–115
anaemia evaluation, 113
augmentation, 116
benzodiazepines, 116
bupropion, 115
C/D agents, 117
complementary and alternative medication, 114
dopaminergic medications, 116
gabapentin, 116
goal of therapy, 113
iron and folate supplementation, 117
iron deficiency, 113–114
near-infrared light (NIR), 114
non-pharmacological treatments, 114
pharmacologic agents, 115
pramipexole, 116
rebound, 116
ropinerole, 116
rotigotine, 116
menopause, hormonal influences in estrogen, 262–263
melatonin, 263
periodic limb movements (PLMs)
fluoxetine, 108
obstructive sleep apnea (OSA), 109
prevalence of, 108
polysomnography (PSG), 108
pregnancy
etiology, 219–220
prevalence during, 218
in pregnancy, 111
vs. SRED, 203–204
symptoms of, 107, 261, 262
Sex hormones, 3–4
Sexomnia treatment, 195
Sleep-disordered breathing (SDB)
clinical characteristics
clinical presentation, 330
Sleep-disordered breathing (SDB) (cont.)
rates of, 329
sleep apnea severity, 328–329
static charge-sensitive bed
technology, 329
estrogen on, 331
HRT, 327–328, 332–333
and pregnancy (see Pregnancy)
symptoms of, 253
Sleep Heart Health Study, 328
Sleep paralysis (SP)
clinical findings, 199
polysomnographic findings, 200
treatment, 200
Sleep-related dissociative disorders
clinical findings, 205–206
polysomnographic findings, 207
treatment, 207
Sleep-related eating disorder (SRED)
clinical findings
epidemiological studies, 203
medications, 202
vs. RLS, 203–204
treatment, 204–205
Sleep terrors
benzodiazepines, 194
clinical findings, 191–192
polysomnographic findings, 192–193
treatment
hypnosis and environmental
change, 195
mood altering medications, 194–195
sexsomnia, 195
Sleep walking
benzodiazepines, 194
clinical findings, 191–192
polysomnographic findings, 192–193
treatment
hypnosis and environmental
change, 195
mood altering medications, 194–195
sexsomnia, 195
Study of Women’s Health Across the Nation
(SWAN), 335
Subjective sleep and awakening (SSA) quality
evaluation of, 271
HRT, 279–281
insomniac postmenopausal syndrome
patients and normal controls
objective sleep variables, 273
sleep profile, 273
thymopsychic, and noopsychic
variables, 274

U
Upper airway resistance syndrome (UARS),
29–30, 138, 336
Uvulopalatopharyngoplasty (UPPP), 146, 165

W
Wakefulness after sleep onset (WASO), 275,
284, 285
Willis–Ekbom disease. See Restless legs
syndrome (RLS)
Wisconsin Sleep Cohort Study (WSCS), 326,
327, 329